CREBBP and acute lymphoblastic leukemia: For instance, the DNA methylation signature can be used to assign BCP-ALL cases to a specific subtype and to predict disease outcome, while loss-of-function mutations in methyltransferases (such as NSD2) or KATS (like CREBBP or EP300) may be used to predict prognosis and response to chemotherapy.